Product Name: TTKSubtide
Product Number: PE-01BJR90
Size: 200 µg      Price:45.00
1 mg      $US91.00
5 mg      214.00
Peptide Name: TTKSubtide

Product Use: For assaying the phosphotransferase activity of Dual specificity protein kinase TTK (UniProt ID P33981).

Peptide Production Method: Solid-phase peptide synthesis

Peptide Sequence: KKLEKNLTPEKKLA

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Molecular Mass Calculated: 1813.19 Da

Peptide Purity Percent after Synthesis and Purification: >90

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Peptide Recommended Enzyme: TTK

Scientific Background: TTK (ESK) is a protein-serine/threonine kinase of the Other group and TTK family. It is a dual specificity protein kinase that can phosphorylate serine, threonine, and tyrosine residues and has a role in cell cycle progression through regulating centrosome duplication during S-phase. This function was CDK2-mediated by direct activation of TTK.. Through CDCA8 phosphorylation TTK can modulate AurKB at the centromere to align the chromosomes. Phosphorylation of S582, T675, T676, T686, and S742 increases phosphotransferase activity. Phosphorylation of T806 inhibits phosphotransferase activity. TTK is a dual-specificity protein kinase with activity toward serine, threonine and tyrosine residues. TTK was found to have a role Overexpression or dysregulation of TTK activtiy may promote cancer through aberrant duplication of centrosomes and promotiong of aneuploidy. Mutations in TTK are highly correlated in the development of microsatellite-unstable colorectal cancers. TTK is linked to pancreatic ductal adenocarcinoma (PDAC), and important in the growth and proliferation of PDAC cancer cells. Triple Negative Breast Cancer (TNBC) is a highly aggressive form of cancer and TTK is consistently upregulated in TNBC tissues.